David J. VanderWeele, M.D., Ph.D.
Dr. VanderWeele’s lab investigates the progression of clinically significant prostate cancer. The lab is interested in the heterogeneity and evolution of the prostate cancer genome, with efforts to identify and target the molecular features that allow prostate cancer subclones to develop metastatic potential and gain clonal dominance. Other work in the lab investigates molecular responses to therapy that lead to development of resistance. The lab uses next-generation sequencing techniques combined with in vitro and in vivo functional studies to accomplish these goals.
Prostate cancer is the most commonly diagnosed cancer in Western men. Though the vast majority of men diagnosed with prostate cancer have indolent disease and die of other causes, it is the second leading cause of cancer death in Western men. Given the morbidity and cost of primary intervention, identifying which men require aggressive treatment remains a key question in the field today. At the same time, metastatic disease is incurable and causes significant morbidity and mortality. All conventional cancers initially respond to androgen deprivation therapy, but there is nearly universal development of resistance and progression.
Our lab is interested in defining and targeting the molecular features that separate organ-confined, curable prostate cancer from metastatic, lethal disease. A number of labs have contributed to a better understanding of the catalogue of alterations that occur in primary, untreated and end-stage, lethal prostate cancer. We are using next-generation sequencing techniques to study the heterogeneity and evolution of the disease, from evaluation of localized, multifocal disease to use of circulating tumor cells at later stages.
Based on these data we conduct functional studies using a number of in vitro and in vivo models of prostate cancer. These studies are designed to evaluate the significance of alterations that appear to be driving prostate cancer progression, and to expose the mechanisms that underly resistance to targeted therapy.
Selected Recent Publications
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.European Urology Focus. [ Journal Article ]
Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.European Urology Focus. [ Journal Article ]
- J Transl Med. 15(1):44: 2017. [ Journal Article ]
- Am J Roentgenol. 206(3):559-65, 2016. [ Journal Article ]
Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate.Urology. 86(4): 777-82, 2015. [ Journal Article ]
Dr. VanderWeele did his Ph.D. in the laboratory of Charles Rudin at the University of Chicago, where he also received his M.D. He did his postdoctoral training in the laboratory of Kevin White in the Institute for Genomics and Systems Biology at the University of Chicago before joining the faculty. In 2015 he came to the Laboratory of Genitourinary Cancer Pathogenesis (LGCP) in the Center for Cancer Research as an Assistant Clinical Investigator.
|Remi Adelaiye-Ogala Ph.D.||Postdoctoral Fellow (Visiting)|
|Yen Thi Minh Nguyen||Postbaccalaureate Fellow (CRTA)|
From Left: Dmitry Grigoryev, David VanderWeele, Yen Nguyen
Yen Nguyen, Postbaccalaureate Fellow
Jose Rodriguez-Nieves Ph.D., Postdoctoral Fellow